# Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice

## TL;DR

This study shows that measuring circulating tumor DNA can predict survival and treatment outcomes in patients with diffuse large B-cell lymphoma.

## Contribution

The study demonstrates that ctDNA levels and MRD status are valuable for risk stratification in DLBCL in real-world clinical settings.

## Key findings

- Baseline ctDNA levels correlated with tumor burden and predicted treatment outcomes.
- Achieving MRD negativity was associated with better treatment outcomes.
- Interim MRD-positivity combined with PET/CT positivity identified a high-risk DLBCL subgroup.

## Abstract

Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B‐cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real‐world studies were limited. Using a targeted sequencing approach (521‐gene panel), we showed that (1) baseline ctDNA level correlated with tumour burden and was an independent predictor of treatment outcome, (2) achievement of minimal residual disease (MRD) negativity was associated with a better treatment outcome and (3) interim MRD‐positivity combined with positron emission tomography/computed tomography scan‐positivity identified a high‐risk subgroup of DLBCL patients. Baseline ctDNA level and treatment related achievement of MRD negativity are valuable prognostic tools in DLBCL to improve risk stratification in routine clinical practice.